Literature DB >> 7606753

Acadesine extends the window of protection afforded by ischaemic preconditioning in conscious rabbits.

B Burckhartt1, X M Yang, A Tsuchida, K M Mullane, J M Downey, M V Cohen.   

Abstract

OBJECTIVE: Ischaemic preconditioning protects myocardium from infarction if the reperfusion interval between the brief and prolonged ischaemic intervals is less than 1 h. In anaesthetised rabbits acadesine (5-amino-4-imidazolecarboxamide riboside, AICAR), an adenosine enhancer which increases tissue adenosine during ischaemia, prolongs the window of protection to 2 h. The aim of this study was to try to determine the maximum extension of this window of protection, using chronically instrumented, unsedated rabbits.
METHODS: Rabbits were instrumented with a balloon occluder around a major branch of the left coronary artery for reversible coronary occlusion. Five to seven days after surgery all animals underwent a 30 min coronary occlusion. Animals were randomised to one of seven groups: (1) No additional treatment (control); (2) Ischaemic preconditioning with 5 min regional ischaemia followed by 10 min reperfusion before the 30 min coronary occlusion; (3) and (4) Ischaemic preconditioning followed by 2 or 4 h of reperfusion before the 30 min occlusion, respectively; (5) Treatment with acadesine (2.5 mg.kg-1.min-1 intravenously for 5 min and then 0.5 mg.kg-1.min-1 beginning 45 min before and continuing until 30 min after release of the 30 min occlusion) without ischaemic preconditioning; (6) and (7) Treatment with the higher dose of acadesine for 5 min beginning 35 min before the 5 min ischaemic period, and then the lower dose continuing until 30 min after release of the 30 min coronary occlusion in rabbits with 4 or 6 h reperfusion intervals, respectively.
RESULTS: Rabbits with ischaemic preconditioning with 10 min reperfusion preceding the 30 min coronary occlusion (group 2) had only 5.6(SEM 1.1)% infarction of the ischaemic zone. Ischaemic preconditioning followed by 2 h reperfusion (group 3) offered continued protection [18.2(2.2)% infarction] as compared to control animals [37.7(2.6)% infarction]. However, protection waned if ischaemic preconditioning was followed by 4 h reperfusion (group 4) [36.7(3.0)% infarction]. Additionally, treatment with acadesine alone did not modify infarct size (group 7) [39.5(4.0)%], but acadesine largely restored the protection of ischaemic preconditioning despite a 4 h reperfusion interval (group 5) [20.4(3.0)% infarction, P < 0.01 v control]. However, when reperfusion was extended to 6 h (group 6) acadesine could no longer restore protection [36.2(0.9)% infarction].
CONCLUSIONS: The protection afforded by a 5 min ischaemic preconditioning period lasts from 2 to 4 h in the awake, unsedated rabbit, and acadesine can extend the duration of this window of protection to at least 4 h but not to 6 h.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606753

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

1.  AMP-activated protein kinase connects cellular energy metabolism to KATP channel function.

Authors:  Hidetada Yoshida; Li Bao; Eirini Kefaloyianni; Eylem Taskin; Uzoma Okorie; Miyoun Hong; Piyali Dhar-Chowdhury; Michiyo Kaneko; William A Coetzee
Journal:  J Mol Cell Cardiol       Date:  2011-08-24       Impact factor: 5.000

Review 2.  Mechanisms of neuroprotection during ischemic preconditioning: lessons from anoxic tolerance.

Authors:  Miguel A Perez-Pinzon
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2006-08-30       Impact factor: 2.320

3.  Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that epsilon is the isoform involved.

Authors:  Y Qiu; P Ping; X L Tang; S Manchikalapudi; A Rizvi; J Zhang; H Takano; W J Wu; S Teschner; R Bolli
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Isoform-selective 5'-AMP-activated protein kinase-dependent preconditioning mechanisms to prevent postischemic leukocyte-endothelial cell adhesive interactions.

Authors:  F Spencer Gaskin; Kazuhiro Kamada; Mozow Yusof Zuidema; Allan W Jones; Leona J Rubin; Ronald J Korthuis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-14       Impact factor: 4.733

Review 5.  AMPK in cardiovascular health and disease.

Authors:  Najeeb A Shirwany; Ming-Hui Zou
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

6.  Demonstration of an early and a late phase of ischemic preconditioning in mice.

Authors:  Y Guo; W J Wu; Y Qiu; X L Tang; Z Yang; R Bolli
Journal:  Am J Physiol       Date:  1998-10

7.  Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury.

Authors:  Marta A Paiva; Zoe Rutter-Locher; Lino M Gonçalves; Luís A Providência; Sean M Davidson; Derek M Yellon; Mihaela M Mocanu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

8.  Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis.

Authors:  Rebeca Kawahara; Anastasia Chernykh; Kathirvel Alagesan; Marshall Bern; Weiqian Cao; Robert J Chalkley; Kai Cheng; Matthew S Choo; Nathan Edwards; Radoslav Goldman; Marcus Hoffmann; Yingwei Hu; Yifan Huang; Jin Young Kim; Doron Kletter; Benoit Liquet; Mingqi Liu; Yehia Mechref; Bo Meng; Sriram Neelamegham; Terry Nguyen-Khuong; Jonas Nilsson; Adam Pap; Gun Wook Park; Benjamin L Parker; Cassandra L Pegg; Josef M Penninger; Toan K Phung; Markus Pioch; Erdmann Rapp; Enes Sakalli; Miloslav Sanda; Benjamin L Schulz; Nichollas E Scott; Georgy Sofronov; Johannes Stadlmann; Sergey Y Vakhrushev; Christina M Woo; Hung-Yi Wu; Pengyuan Yang; Wantao Ying; Hui Zhang; Yong Zhang; Jingfu Zhao; Joseph Zaia; Stuart M Haslam; Giuseppe Palmisano; Jong Shin Yoo; Göran Larson; Kai-Hooi Khoo; Katalin F Medzihradszky; Daniel Kolarich; Nicolle H Packer; Morten Thaysen-Andersen
Journal:  Nat Methods       Date:  2021-11-01       Impact factor: 28.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.